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Summary
Virulence of Plasmodium falciparum, the most lethal
parasitic disease in humans, results in part from
adhesiveness and increased rigidity of infected
erythrocytes. Pf332 is trafficked to the parasite-
infected erythrocyte via Maurer’s clefts, structures for
protein sorting and export in the host erythrocyte.
This protein has a domain similar to the Duffy-
binding-like (DBL) domain, which functions by
binding to receptors for adherence and invasion. To
address structure of the Pf332 DBL domain, we
expressed this region, and validated its fold on the
basis of the disulphide bond pattern, which con-
formed to the generic pattern for DBL domains. The
modelled structure for Pf332 DBL had differences
compared with the erythrocyte-binding region of the
aDBL domain of Plasmodium knowlesi Duffy-binding
protein (Pka-DBL). We addressed the function of
Pf332 by constructing parasites that either lack
expression of the protein or express an altered form.
We found no evidence that Pf332 is involved in
cytoadhesion or merozoite invasion. Truncation of
Pf332 had a signiﬁcant effect on deformability of the
P. falciparum-infected erythrocyte, while loss of the
full protein deletion did not. Our data suggest that
Pf332 may contribute to the overall deformability of
the P. falciparum-infected erythrocyte by anchoring
and scaffolding.
Introduction
Malaria is a major disease in humans with over 500 million
cases of infection and 1–3 million deaths every year
(Snow et al., 2005). Plasmodium falciparum is the proto-
zoan parasite responsible for the severe form of this
disease causing nearly all malaria deaths and most of the
morbidity. The blood stage of the parasite infects circulat-
ing erythrocytes. Once inside it initiates a remarkable
remodelling process that converts a terminally differenti-
ated cell lacking fundamental structures and functions into
a host in which the parasite can grow and survive
(see for review Marti et al., 2005). The properties of
the P. falciparum-infected erythrocytes are dramatically
altered becoming more rigid and imparting the ability of
the host cell to adhere to endothelial and other cell types.
The altered properties of the parasite-infected red cells
play an important role in pathogenesis of malaria (see for
review Miller et al., 2002).
ThepropertiesofP. falciparum-infectederythrocytesare
mediated by parasite proteins exported into the host cell
and deposited beneath and onto the host cell membrane.
These proteins are trafficked in a multistep process requir-
ingtransferacrossseveralmembranes,includingthepara-
site and parasitophorous vacuole membrane, and the
erythrocyte membrane after transport through the host
cell cytoplasm (Marti et al., 2005). Trafficking of proteins
beyond the parasitophorous membrane requires these
molecules to associate with membranous structures in the
P. falciparum-infected erythrocytes called Maurer’s clefts.
These structures bud from the parasitophorous vacuole
membrane and transport proteins to the periphery of the
erythrocyte allowing sorting and transfer to the underside
oftheerythrocytemembraneand,forsomeproteins,inser-
tion into the host cell membrane (Waterkeyn et al., 2000;
Wickham et al., 2001; Lopez-Estrano et al., 2003). The
surface of the parasite-infected erythrocyte becomes
covered with elevations called knobs, which consist prima-
rily of the knob-associated histidine-rich protein (KAHRP)
(Kilejian, 1979; Culvenor et al., 1987). Adherence of
P. falciparum-infected erythrocytes is mediated by P. falci-
parum erythrocyte membrane protein 1 (PfEMP1) (Leech
et al., 1984), a large and antigenically diverse protein
family that is expressed after invasion of the erythrocyte. It
is trafficked to the host cell surface via Maurer’s clefts
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et al., 1995; Smith et al., 1995; Su et al., 1995).
Pf332 is a large protein of approximately 700 kDa that
localizes to Maurer’s clefts and has been reported to be
trafficked to the surface of the P. falciparum-infected eryth-
rocyte (Mattei and Scherf, 1992; Mattei et al., 1992). This
protein has a Duffy-binding-like (DBL) domain at the
N-terminus followed by a putative transmembrane region
and a very large C-terminus that is highly charged and
repetitive with respect to the amino acid sequence (Moll
et al., 2007). It has been suggested that Pf332 plays a role
in merozoite invasion as the DBL domain has been
expressed in Chinese hamster ovary (CHO) cells and
Escherichia coli and was shown to bind erythrocytes (Moll
et al., 2007) and antibodies to the DBL domain inhibited
invasion in a number of P. falciparum strains (Ahlborg
et al., 1996).Antibodies to the C-terminal region have also
been shown to inhibit in vitro growth of P. falciparum
although in this case they appeared to interfere with late-
stageparasitedevelopmentandtheeffectwaslikelydueto
cross-reaction with other proteins (Ahlborg et al., 1996).
The DBL domain is Plasmodium spp. speciﬁc shared
by a number of protein families that include the DARC
(Duffy antigen receptor for chemokines)-binding protein
from Plasmodium knowlesi (Pka-DBL). The erythrocyte-
binding-like proteins (ebl) of P. falciparum also contain
DBL domains (Adams et al., 2001) and this family con-
sists of EBA-175, EBA-181 (also known as JESEBL) and
EBA-140 (also known as BAEBL), which are proteins that
play a key role in invasion of the merozoite form of the
parasite into human erythrocytes by binding to speciﬁc
host receptors (see for review Cowman and Crabb, 2006).
The three-dimensional structures of the DBL domains
from EBA-175 and Pka-DBL have been solved (Tolia
et al., 2005; Singh et al., 2006).
Here we have expressed and refolded the DBL domain
of Pf332 and determined the disulphide topology using
a combination of reversed-phase (RP)-HPLC peptide
mapping under reducing and non-reducing conditions and
subsequent Edman degradation and mass spectroscopic
analysis of the identiﬁed disulphide-linked peptides.
These data have been used to validate a modelled struc-
ture of Pf332 DBLdomain, which signiﬁcantly differs in the
region corresponding to the site identiﬁed in Pka-DBL that
binds to DARC on erythrocytes (Choe et al., 2005). We
also describe targeted mutagenesis and disruption of the
Pf332 gene to test its role in cytoadherence and merozo-
ite invasion and deformability.
Results
Expression and oxidative in vitro refolding of the
recombinant Pf332 DBL domain
Under the cell culture conditions utilized, the cysteine-rich
DBL domain of Pf332 was deposited in E. coli exclusively
as inclusion bodies. A denaturing buffer, containing 6 M
guanidine, was used to solubilize and extract the Pf332
DBL domain. The domain fragment was puriﬁed from
whole-cell lysate by passage over NiNTA agarose resin,
giving approximately 80–90% purity of the material
in a single chromatographic step (Fig. 1A). The dena-
tured domain fragment was then oxidatively refolded in
vitro prior to puriﬁcation using strong anion-exchange
chromatography. Fractions collected from the ion
exchange are shown (Fig. 1A). Only those fractions that
contained the DBL domain monomer were pooled (e.g.
fractions 13 and 14) as later eluting fractions contained
covalent multimers, which occur as a by-product of the
oxidative refolding process. Noteworthy is the differential
migration of the Pf332 monomer when electrophoresed
in the presence of reducing and non-reducing sample
buffers. This observation is consistent with the monomer
having a disulphide bond architecture which inﬂuences
the binding of sodium dodecylsulphate (SDS) to Pf332
DBL domain, resulting in a faster rate of migration than
that observed for the reduced material. RP-HPLC was
used to demonstrate that a decrease in the DBL domain’s
hydrophobicity had occurred as a result of the in vitro
refolding process. The refolded material eluted signiﬁ-
cantly earlier than the denatured starting material consis-
tent with internalization of hydrophobic residues upon
refolding (Fig. 1B). The monomeric form of the DBL
domain for Pf332 was found to be quite stable for
extended periods at 4°C hence indicating no reactive
surface accessible Cys residues were present in the ﬁnal
product.
The refolded antigen was used to immunize rabbits
and mice to produce polyclonal and monoclonal antibod-
ies and their speciﬁcity was determined on saponin-
lysed parasitized erythrocytes. Both rabbit and mouse
polyclonal antibodies produced similar proﬁles on immu-
noblots and reacted with several very high-molecular-
weight protein bands (> 250 kDa) when electrophoresed
in the presence of reducing and non-reducing sample
buffers on 3–8% Tris-acetate gels (Fig. 1C). Several
monoclonal antibodies raised to the recombinant Pf332
DBL domain, including 10H2, also gave similar staining
patterns on immunoblots as seen for the polyclonal sera,
and it appears that the Pf332 parent molecule under-
goes signiﬁcant proteolytic breakdown in schizont-stage
parasites (Fig. 1C and D). However, the monoclonal
antibodies failed to signiﬁcantly react against the two
largest protein bands when samples were electrophore-
sed in reducing sample buffer. This observation is prob-
ably due to these monoclonal antibodies targeting
a reduction-sensitive epitope that may reform in the
lower-molecular-weight (~250 kDa) species during
electrophoresis.
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In order to further characterize the conformation of the
Pf332 DBL domain the refolded protein was digested
extensively in trypsin and disulphide-linked peptides
were identiﬁed by comparison of analytical RP-HPLC
proﬁles for DTT-reduced and non-reduced digests in a
manner similar to that described previously (Hodder
et al., 1996) (Fig. 2). Those peaks containing disulphide-
linked peptides were identiﬁed by their altered chromato-
graphic behaviour after reduction with DTT and are
labelled with an asterisk (Fig. 2A). The procedure was
then scaled up using the same column and elution con-
ditions and the contents of the peaks of interest identi-
ﬁed using a combination of Edman degradation and
mass spectrometric analysis (Fig. 2B and Table 1). The
disulphide linkages between 8 of the 12 Cys residues in
the DBL domain were resolved without further sample
processing; however, Cys-69, Cys-73, Cys-140 and Cys-
144 were all found to be in a trypsin resistant tri-peptide
bundle: the localization of Cys-69 and Cys-73 within the
same peptide revealed that each of these residues was
linked to an alternative Cys residue (either Cys-140 or
Cys-144) within one of the other peptides. Interestingly,
these four Cys residues are from subregion II in the DBL
domain where only a single disulphide linkage has pre-
viously been determined (Singh et al., 2006). The pres-
ence of acidic residues between Cys-69 and Cys-73
enabled use of AspN protease to promote restricted
cleavage speciﬁcally at Glu residues. Mass spectrometry
was subsequently used to analyse the subdigest of peak
fraction 34 and the remaining two disulphide-bond link-
ages were resolved by the observation of molecular ions
that corresponded to the theoretical ion mass for the
expected cleavage products of the known tri-peptide
sequence. The disulphide-bond linkages determined in
the Pf332 DBL domain are listed Table 1.
Fig. 1. Production and characterization of the recombinant Pf332 DBL domain.
A. SDS-PAGE analysis of denatured Pf332 DBL domain solubilized from inclusion bodies then puriﬁed using NiNTA agarose. After the
oxidative, in vitro refolding process, correctly refolded Pf332 DBL domain (AEX fractions #13 and #14) was separated from soluble multimers
by anion-exchange chromatography (AEX). All samples shown in (A) were electrophoresed in sample buffer with (RD) or without (NR)
reducing agent as indicated.
B. RP-HPLC analysis of the denatured starting material (SM) and the refolded Pf332 DBL domain (R). A decreased retention time is
consistent with protein refolding. AUFS, Absorbance units full scale.
C and D. Immunoblots for saponin-lysed P. falciparum 3D7 strain parasites were probed with (C) polyclonal mouse serum and (D) monoclonal
antibody 10H2 each raised to the refolded Pf332 DBL domain. Parasite samples were electrophoresed with (RD) or without (NR) reducing
agent in the sample buffer, then transferred onto PVDF membrane prior to commencing immunoblots.
50 A. N. Hodder etal. 
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd, Molecular Microbiology, 71, 48–65A comparison of the disulphide-linkage pattern in the
DBL domains for EBA-175, Pka-DBL and Pf332
A molecular model of Pf332 DBL domain was produced
using the EBA-175 structure as a template (Tolia et al.,
2005).Asimilarity comparison of the Pf322 DBL and EBA-
175 F2 domains revealed signiﬁcant homology (Fig. S1).
This structure enabled the comparison of the overall
pattern and location of the disulphide bonds within
the DBL domain of Pf332 with that of another well-
characterized single DBL domain from Plasmodium
involved in binding erythrocytes (Figs 3 and 4) (Tolia
et al., 2005; Singh et al., 2006). The Pka-DBL domain
contains 12 Cys residues compared with 14 Cys residues
in the EBA-175 F2 DBL domain. A structural comparison
for these two proteins reveals that the disulphide-bond
pattern is identical in both proteins, except that the Cys-
7–Cys-12 linkage in subregion 3 is missing in Pka-DBL.
The disulphide-bond pattern for Pf332 was found to be
similar but not identical to that found for the EBA-175 F2
DBL domain, with three signiﬁcant differences observed.
First, as for the Pka-DBL domain, a disulphide bond was
found to be missing from subregion 3; however, the Cys-
9–Cys-14 linkage was lost in the Pf332 DBL domain
instead of the Cys-7–Cys-12 disulphide bond. Second,
the Cys-1–Cys-4 disulphide bond found in subregion 1 of
both EBA-175 F2 and Pka-DBL domains was not present
in the Pf332 DBL domain (Fig. 3). The ﬁrst and second
cysteine residues (i.e. Cys-15 and Cys-21) in the mature
sequence of Pf332 correspond to the Cys-2 and Cys-3
residues in EBA-175 F2 and Pka-DBL domains (Figs 3
and 4). This conclusion is supported not only by their
location in the modelled structure of the Pf332 DBL
domain (Fig. 4), but also by their location relative to con-
served residues in the protein sequence. For example,
Trp-13 located two amino acid residues on the N-terminal
side of Cys-15 and the Pro–Pro–Arg–Arg motif located on
the C-terminal side of Cys-21. Third, an additional, previ-
ously unreported, disulphide linkage was determined
between Cys-5a (Cys-69) and Cys-6a (Cys-140) in sub-
region 2. The existence of the disulphide bond between
Cys-69 and Cys-140 was conﬁrmed experimentally in the
in vitro refolded recombinant DBL domain (Table 1) and
was also predicted to occur between these two cysteines
residues in the modelled structure. In this structure
Cys-69 and Cys-140 were found to interact within a van
der Waals radius of each other with the correct spatial
orientation for disulphide bond formation (Fig. 4). The
Cys-5a–Cys-6a linkage is located on the same face of the
protein as the Cys-5–Cys-6 linkage.
Fig. 2. Identiﬁcation and puriﬁcation of disulphide-bonded
peptides from a tryptic digest of Pf332 DBL domain.
A. Comparison of the analytical RP-HPLC elution proﬁles for
DTT-reduced and non-reduced tryptic digest of refolded Pf332 DBL
domain. Reduced (upper trace) and non-reduced (lower trace)
digests (20 mg) were fractionated on a Vydac C18 (4.6 mm inner
diameter ¥ 250 mm) column under identical chromatographic
conditions. The column was developed at a ﬂow rate of 1 ml min
-1
with a linear 120 min gradient from 0 to 70% buffer B, where buffer
A was 0.05% (v/v) triﬂuoroacetic acid in Milli Q water, and buffer B
was 0.05% (v/v) triﬂuoroacetic acid in acetonitrile. Asterisk-labelled
peaks within the non-reduced chromatogram represent those
altered by DTT reduction.
B. Preparative scale RP-HPLC puriﬁcation of peptides from the
tryptic digest of Pf332 DBL domain. A total of 125 mg of digest was
fractionated by elution from a Vydac C18 column (4.6 mm inner
diameter ¥ 250 mm) column using the elution conditions described
in (A). Peptide fractions found to contain disulphide-bonded
peptides by Edman degradation and mass spectrometry are
indicated by peak numbers and correspond to those given in
Table 1 (see Experimental procedures for further details).
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binding to the DARC on erythrocytes are absent from
the predicted interaction site in the Pf332 DBL domain
It is envisaged that two domains sharing a similar fold
and the same function would interact with erythrocytes
via a similar binding mechanism. In the Pka-DBL domain
(pink backbone), Tyr-94, Leu-168 and Ile-175 form
a hydrophobic pocket to promote interaction with the
DARC on erythrocytes (Choe et al., 2005). However, a
hydrophobic pocket does not occur between juxtaposi-
tioned residues within the equivalent region of the Pf332
DBL domain (Fig. 4B). Interestingly, the additional disul-
phide bond between Cys-5a and Cys-6a was found to
occur in the same area suggesting a restricted or stabi-
lized conformation was required in this region of the
DBL domains. Additionally, the essential polar residues
involved in DARC recognition in Pka-DBL (Asn-95,
Lys-96 and Arg-103 – Pka-DBL numbering) were also
absent in Pf332.
The cluster of basic residues (Lys-100 and Lys-177 on
subdomain II, and Arg-193 and Arg-197 on subdomain III
–P k a-DBLnumbering) which also form the remaining part
of the DARC binding site in Pka-DBL domain, which may
bind the sulphonated Tyr-41 of DARC (Choe et al., 2005),
are not observed in the equivalent region of the Pf332
DBL structure (Fig. 4B). Instead an increased density of
acidic residues (i.e. residues Glu-70, Glu-71,Asp-74, Glu-
165 and Glu-151) was evident, which would be expected
to present a very different surface polarity in this region
compared with that found in Pka-DBL (Singh et al., 2006).
The surface topographies generated for the DARC
binding site and the equivalent region in Pf332 varied
signiﬁcantly and resulted from quite different amino acid
compositions in this region of the molecules (Fig. 4C).
Particularly noteworthy was the formation of a ridge by the
Cys-5a and Cys-6a disulphide bond through the area
equivalent to the hydrophobic pocket in Pka-DBL and the
large cavity observed in Pf332 instead of the cluster of
basic residues in Pka-DBL.
Disruption of the Pf332 gene in P. falciparum-infected
erythrocytes
To analyse the function of Pf332 in P. falciparum, we dis-
rupted the corresponding gene (PF11_0506) by double-
cross-over homologous recombination (Fig. S2). In
addition, we generated a second parasite line expressing
a truncated form of the Pf332 (Fig. S2). Expression of the
truncated protein in CS2Pf332trunc and absence of
Pf332 in CS2DPf332 was conﬁrmed using immunoblots
with Pf332 monoclonal antibody 10H2 (Fig. 5). High-
molecular-weight bands of approximately 700 kDa and
400 kDa were observed for cloned parental line CS2,
whereas CS2Pf332trunc showed a major band of approxi-
mately 90 kDa, which corresponds to the predicted theo-
retical size of 87.3 kDa. There was no reactivity of the
Table 1. Assignment of cysteine connectivities within the Pf322 DBL domain using N-terminal sequencing and ion-trap spectrometric data.
Peak
number
Cysteine
connectivities
a Amino acid sequence
b
Peptide
yields
(picomoles) Residues
c
Mass
observed
(Da)
Mass
calculated
(Da)
Tryptic peaks 34 1–2 (-)GAMGSTEWNCK(E)
d [13] 10–16 2152.11 2151.93
(K)EDVGCVPPR(R) [12] 17–25
35 3–6 (R)EKHDESCDEFCDAWNR(S) [23] 63–78 3606.57 3606.43
(R)ENGLDVCK(S) [22] 134–141
(K)SQCEER(S) [22] 142–147
57 7–11 (R)FFAEWEEEFCDGLNK(H) [114] 159–173 2111.02 2110.89
(K)CK(V) [26] 235–236 1255.49 1255.56
11 8–9 (K)SCTK(D) [25] 180–183
(K)DINCDIK(D) [18] 184–190
29 10–12 (K)CSNFK(D) [10] 191–195 1648.77 1648.72
(K)SGFANVAECR(N) [11] 246–255
AspN subdigestion
of peak 35
3–5 (H)DESC(D) 66–69 1327.51 1327.51
(R)ENGLDVVCK(S) 134–141
(R)EKHDESC(D) 63–69 1721.71 1721.71
(R)ENGLDVCK(S) 134–141
4–6 (C)DEFCDAWNR(S) 70–78 1903.73 1903.73
(K)SQCEER(S) 142–147
a. Numbers refer to relative position of cysteines in amino acid sequence.
b. One-letter abbreviations used for amino acids; amino acids in parenthesis represent residues immediately each side of the tryptic peptide in
the protein sequence.
c. Indicates residue number determined from the protein sequence information available in PlasmoDB for gene Pf11_0506.
d. GAMG are four residual amino acid residues derived from the pProExHT vector and are left at the N-terminus of the bacterially expressed Pf332
DBL domain after removal of the hexa-His fusion tag by TEV protease.
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ruption and demonstrating the speciﬁcity of this antibody.
The temporal expression pattern of Pf332 was deter-
mined using speciﬁc antibodies to show that both the
full-length protein in CS2 and the truncated form in
CS2Pf332trunc were expressed during the asexual blood
stage in trophozoite stages. Immunoblot analysis with
anti-Pf332 antibodies demonstrated that this protein was
expressed primarily between 28 and 32 h post invasion,
which corresponds to late trophozoite stages (Fig. 5D).
This is consistent with the transcription pattern of Pf332
as demonstrated using microarray analysis (Bozdech
et al., 2003; Le Roch et al., 2003) and previous analysis of
Pf332 expression (Moll et al., 2007).
To determine the subcellular localization of Pf332 para-
sites were labelled using a speciﬁc monoclonal antibody
and colocalized with skeleton-binding protein 1 (SBP1), a
known Maurer’s clefts marker in the P. falciparum-infected
erythrocyte (Blisnick et al., 2000). The Pf332 protein could
not be detected in ring stages (Fig. 6A, a); however, it was
strongly expressed in trophozoite and schizont stages
showing colocalization with SBP1 in Maurer’s clefts con-
sistent with previous subcellular localization of this protein
(Fig. 6A, b and c) (Moll et al., 2007). The truncated Pf332
protein in CS2Pf332trunc showed the same subcellular
localization in Maurer’s clefts as the wild-type protein
showing that the necessary signals for correct trafficking
were contained within this 87 kDa region (data not
shown). No expression of Pf332 could be detected in free
merozoites (Fig. 6A, d and e); however, material that
resembled intact Maurer’s clefts was located outside sch-
izont stages suggesting that they were released on
rupture of the cell (Fig. 6A, e). Both Pf332 and SBP1
localized to these structures consistent with release of
Maurer’s clefts on erythrocyte rupture (Fig. 6A, e, white
arrows). Expression of Pf332 was, as expected, absent in
CS2DPf332 (Fig. 6A, f). Similar subcellular localization
results and Pf332 detection were obtained using the
rabbit polyclonal anti-Pf332 antibodies (data not shown).
An interesting feature that became evident with colocal-
ization of Pf332 and SBP1 to Maurer’s clefts was that the
former protein was not present in these structures in ring
stages, as this protein is expressed later in the blood-
stage life cycle. Therefore Maurer’s clefts are released
from the parasitophorous vacuole in ring stages with
cargo such as SBP1 before Pf332 is expressed. Maurer’s
Fig. 3. Analysis of the disulphide bond
patterns within known DBL domains.
A. Disulphide-bond linkage patterns for Pf
EBA-175 F2, Pk DBP and Pf332 DBL
domains. Cysteine residues are numbered
relative to their occurrence in the protein
sequence and are clustered by their location
in either subregion 1, 2 or 3 (R1, R2, R3) in
the DBL domain. Crossed (red) Cys residues
have been lost from the sequence and result
in the subsequent loss of the corresponding
disulphide bond from the protein structure,
relative to the EBA-175 F2 DBL domain.
B. A two-dimensional schematic
representation of the Pf EBA-175 F2 DBL
domain showing the relative position of
disulphide bonds (yellow) in Pf332 and Pk
DBP DBL domains. Those disulphides lost
from either structure are circled in red. The
start of the Pf332 DBL sequence relative to
the two other DBL domains is indicated by
parallel red lines between the Cys-1 and
Cys-2 residues. Structurally relevant helices
are represented as black cylinders and are
labelled h1–h8. Dashed lines (black)
represent regions where sequence has not
been considered.
For the Pf332 DBL domain C2 = Cys-15,
C3 = Cys-21, C5a = Cys-69, C5 = Cys-73,
C6a = Cys-140, C6 = Cys-144, C7 = Cys-168,
C8 = 181, C10 = 187, C11 = Cys-191,
C12 = Cys-235 and C13 = Cys-254.
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Pf332 contain this protein. Therefore there is a mixed
population of Maurer’s clefts structures that are formed
from the parasitophorous vacuole through ring and tro-
phozoite stages that contain different protein cargoes
(Fig. 6A, a and b).
Conﬁrmation of Pf332 localization to Maurer’s clefts
was obtained using immunoelectron microscopy in
which consistent labelling was obtained on these struc-
tures with some speciﬁc labelling of electron-dense
material within the P. falciparum-infected erythrocyte
(Fig. 6B). Labelling could also be observed in the
erythrocyte cytoplasm and the parasitophorous vacuole
membrane (Fig. 6B).
The Pf332 DBL domain does not bind to erythrocytes or
play a role in merozoite invasion
The Pf332 DBLdomain has been previously expressed as
a glutathione-S-transferase fusion protein and reported to
interact with the erythrocyte surface (Blisnick et al., 2000).
We expressed a similar DBL region as a single refolded
domain and used this protein in erythrocyte binding
assays. However, no binding of erythrocytes could be
detected in multiple experiments using different batches
of the DBL domain (data not shown). While we have
shown that Pf332 is not expressed in merozoites we
investigated the possibility that this protein was released
into the supernatant, which would potentially allow it to
Fig. 4. Analysis of the structure for the
Pf332 DBL domain.
A. Schematic representations of the structures
for the DBL domains of Pka-DBL (magenta)
and that modelled for Pf332 (blue). The
disulphide-bond pattern, determined via tryptic
digestion of the refolded protein and from
modelling the structure of Pf332 DBL domain,
is compared with that found in the structure of
Pka-DBL (PDB 2C6J). Cysteine residues are
numbered and displayed in yellow.
B. A comparison of the DARC binding site
from Pka-DBL and the equivalent region in
Pf332. Basic residues are shown in blue and
acidic residues are shown in red. The four
non-polar residues considered important for
binding a sulphated tyrosine on the DARC
receptor (Y94, N95, L168 and I175) are
shown in the colour of the Pka-DBL
backbone. The Cys-5a–Cys-6a disulphide
bond is shown in yellow.
C. The surface topographies resulting from
the differences in amino acid composition in
the DARC binding site for Pka-DBL domain
and the equivalent region in the Pf332 DBL
domain.
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invasion. Immunoblots of parasite supernatants after sch-
izont release were analysed to detect any soluble Pf332
DBL domain. It was not possible to detect this domain in
supernatant from these ruptured erythrocytes (Fig. S3)
indicating the protein was retained in the insoluble mem-
branous material and suggesting furthermore that it is not
released from Maurer’s clefts (data not shown). This is
consistent with the presence of seemingly intact Maurer’s
clefts outside parasite-infected erythrocytes as shown by
immunoﬂuorescence (Fig. 6A, e). Additionally, we found
that the antibodies to the refolded Pf332 DBL domain
were not able to inhibit merozoite invasion in growth inhi-
bition experiments (data not shown). Combined, the
above data are consistent with Pf332 not playing a role in
merozoite invasion nor is the protein present in a local-
ization consistent with any role in this parasite function.
The DBL domain of Pf332 is not exposed on the
surface of CS2-infected erythrocytes
Previously, Pf332 was detected on the P. falciparum-
infected erythrocyte surface by immunoﬂuorescence with
polyclonal antibodies to a recombinant DBLdomain for the
strains FCR3 and HB3 (Moll et al., 2007). Using live
CS2DPf332-infected erythrocytes lacking expression of
Pf332 as a negative control we tested whether this protein
was exposed on the host cell surface with the monoclonal
antibody in immunoﬂuorescence experiments (Beeson
et al., 2006). The CS2 cloned line is derived from ItG2 and
is essentially the same parasite line as most laboratory
FCR3 strains due to a contamination event before distri-
bution of these parasites around the world (Rubio et al.,
1995). No reactivity with the monoclonal antibody was
observedforCS2witheitherfreemerozoitesortrophozoite
stages suggesting that Pf332 was located neither on the
surface of the parasite invasive stage nor on the infected
erythrocyte (Fig. 6C, a and b), which is in contrast to
previous results (Moll et al., 2007). Similar results were
observedforthestrains3D7andHB3(datanotshown).As
positive controls we used antibodies to MSP1 and human
serum from an individual living in a malaria-endemic
region. As expected the MSP1 antibodies and the human
serum reacted with the surface of the merozoite and
trophozoite-infected erythrocyte respectively (Fig. 6C,
c and d) (Holder and Freeman, 1982). A monoclonal
antibody to PfEMP3, a protein located underneath the
P. falciparum-infected erythrocyte membrane, was used
as negative control and as expected showed no reactivity
(Waterkeyn et al., 2000) (Fig. 6C, e).The monoclonal anti-
body against Pf332 only gave speciﬁc ﬂuorescence when
the erythrocyte membrane was permeabilized indicating
that this antibody could detect the DBL domain of this
proteinineachofthestrainstestedbutnotinliveandintact
parasites or parasite-infected erythrocytes (Fig. 6C, f).
FACS analysis with increasing concentrations of antibody
conﬁrmed this result as Pf332 was not detectable on live
parasite-infected erythrocytes (Fig. 7A). These results are
consistent with Pf332 not being located on the CS2, HB3
and 3D7 P. falciparum-infected erythrocyte surface.
To further conﬁrm that Pf332 was absent from the
surface of P. falciparum-infected erythrocytes we used
an assay developed for detecting surface expression of
PfEMP1 (Waterkeyn et al., 2000). Trypsin treatment of
CS2-infected erythrocytes results in digestion of the
surface PfEMP1 ectodomain leaving the cytoplasmic
acidic terminal sequence (ATS), which can be detected
with antibodies raised to the C-terminus of the protein
(Fig. 7B). The PfEMP1 protein and the residual cytoplas-
mic region remaining after tryptic digestion were Triton
X-100 insoluble and SDS soluble as was the Pf332
protein. Identically treated samples were probed with anti-
Pf332 antibodies that react with the large repetitive
cytoplasmic domain. P. falciparum-infected erythrocytes,
which were treated with and without trypsin, gave an
identical band pattern on immunoblots, with the dominant
Pf332 bands visible at approximately 700 and 400 kDa
(Fig. 7B). This outcome is consistent with Pf332 not being
exposed on the surface of P. falciparum-infected erythro-
cytes and remaining localized to Maurer’s clefts.
Fig. 5. Western blot of saponin pellets of trophozoite-infected
erythrocytes with CS2, CS2Pf332trunc and CS2DPf332 using
monoclonal antibody 10H2 that is speciﬁc for the Pf332 DBL
domain. Time-course across the asexual blood stage with equal
number of parasites added to each lane showing maximal
expression of Pf332 full length and the Pf332 truncation in
trophozoite stages. Parasite pellets from synchronized CS2
parasites taken at 8 h intervals were separated by SDS-PAGE,
transferred to nitrocellulose and probed with the mouse anti-Pf332
10H2 monoclonal antibody. Anti-PfHSP70 antibodies shown at the
bottom of each panel was used to conﬁrm correct development of
the parasites across the asexual blood stage.
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A. Localization of Pf332 in ring stage-infected erythrocytes (R) (a), trophozoite-infected erythrocytes (T) (b) and schizont-infected erythrocytes
(S) (c). Each panel contains from left to right: bright ﬁeld, DAPI-stained nuclei, anti-Pf322, anti-SBP1 and overlay of all four. Free merozoites
(M) are shown in d. d is as above except that the fourth panel was labelled with anti-MSP1 antibodies. Panel row e contains free merozoites
and material positive for both Pf332 and SBP1 suggesting Maurer’s clefts (white arrows) that were released during schizont rupture. Panel row
f shows CS2DPf322 schizont-infected erythrocytes (S). The order of each panel is as described above.
B. Transmission electron microscopy performed on high pressure frozen and freeze substituted sections of CS2-infected erythrocytes. The
sections were labelled with either rabbit or mouse anti-Pf332 antibody and show the distribution of Pf332 in the red blood cell cytosol (a and
b) and on Maurer’s clefts (c and inset).
C. Live IFA on CS2-infected erythrocytes to determine whether Pf332 is on the surface of merozoites and/or trophozoite-infected erythrocytes.
The ﬁrst column of each row shows a bright ﬁeld image, the second column a nuclear stain (DAPI), the third column reactivity with mouse mono-
clonal anti-Pf332 antibody and the last column an overlay of the previous three columns. Panels a and b: reactivity of anti-Pf332 antibodies with
free live merozoites (M) and trophozoite (T)-infected erythrocytes to test for surface localization. Panel c: control panel with free live merozoites
labelled with anti-MSP1 antibodies. Panel d: control panel with live trophozoites labelled with human serum (HS) from an individual living in a
malaria-endemic region. Panel e: control panel with anti-PfEMP3 antibodies with live trophozoite-infected erythrocytes. Panel f: IFA on
trophozoite-infected erythrocytes permeabilized with Triton X-100 to prove reactivity of the mouse monoclonal anti-Pf332 antibody.
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same solubility characteristics.
PfEMP1 export is not affected in CS2DPf332-infected
erythrocytes
Pf332 is expressed and trafficked to Maurer’s clefts when
PfEMP1 begins to appear on the erythrocyte surface
suggesting it may play a role in transfer of this virulence
protein to the erythrocyte surface (Waterkeyn et al.,
2000). To investigate whether trafficking and display of
PfEMP1 is affected by the truncation or deletion of Pf332,
we performed trypsin cleavage assays to detect the
surface pool of this protein (Fig. 7C) (Waterkeyn et al.,
2000). As above, cultures were treated with trypsin,
and PfEMP1 protein detected using antibodies to the
Fig. 7. Pf332 is not located on the surface of P. falciparum-infected erythrocytes and not required for surface localization of PfEMP1.
A. FACS analysis of P. falciparum-infected trophozoites to test for the presence of Pf332 on the surface with increasing amounts of anti-Pf332
antibodies. The control sera R1945 was made by repeated injection of live CS2 parasites into rabbits.
B. Trypsin treatment of CS2-infected erythrocytes to determine surface localization for Pf332 compared with PfEMP1. The ﬁrst panel contains
parasites either treated or not treated with trypsin and differentially solubilized to show that PfEMP1 is sensitive to trypsin and contained within
the Triton X-100-insoluble/SDS-soluble fraction. The second panel shows the same samples probed with anti-Pf332 antibodies to show that
the protein is resistant to trypsin in intact cells and that it is also within the Triton X-100-insoluble/SDS-soluble fraction.
C. Trypsin treatment of intact erythrocytes infected with CS2, CS2Pf332trunc and CS2DPf332 to determine the presence of PfEMP1 on the
surface of the host erythrocyte. For each cell line three lanes are shown: treatment without (-) and with (+) trypsin and treatment with trypsin
in the presence of trypsin inhibitor (i). Full-length PfEMP1 and its cytoplasmic tail were detected using antibodies to the cytoplasmic acidic
terminal segment (ATS). Full-length PfEMP1 was detected as a > 300 kDa band. Surface exposed PfEMP1 was cleaved by trypsin and results
in the detection of bands between 70 and 90 kDa.
D. IgG binding to the surface of CS2- and CS2DPf332-infected erythrocytes using sera from malaria-exposed multigravid women from Papua
New Guinea (samples A–I) compared with sera from Melbourne residents as non-exposed controls (Samples N1–5). Values are means
(+SEM) from three experiments in duplicate.
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plasmic side of the infected erythrocyte membrane. In
CS2 a large protein band of over 300 kDa was detected
by anti-ATS antibody, representing the full-length protein.
In the absence of trypsin, or when the action of trypsin
was inhibited by soybean trypsin inhibitor, only full-length
PfEMP1 was observed, whereas the addition of trypsin
leads to the detection of products of 70 and 90 kDa.
These bands represent the protected intracellular
PfEMP1 domain (ATS and transmembrane region)
after cleavage of surface-exposed PfEMP1. Full-length
PfEMP1 can also be detected in trypsin treated cells,
which represents the non-exposed PfEMP1 pool in these
cells. In the three cell lines, CS2, CS2Pf332trunc and
CS2DPf332, PfEMP1 was clearly located on the surface.
CS2- and CS2DPf332-infected erythrocytes had approxi-
mately the same levels of surface PfEMP1 indicating
correct trafficking and exposure of this protein indepen-
dent of Pf332 function. However, the CS2Pf322trunc-
infected erythrocytes appeared to have a decreased level
and this may be due to a dominant-negative effect as was
seen previously when PfEMP3 was truncated (Waterkeyn
et al., 2000). Truncation of PfEMP3 resulted in partial
blockage of PfEMP1 so that decreased levels were trans-
ferred to the infected erythrocyte surface. When a para-
site lacking expression of the full PfEMP3 protein was
constructed this effect disappeared suggesting the block-
age was physical rather than a direct effect on function
(i.e. a dominant-negative effect) (Waterkeyn et al., 2000).
The presence of similar amounts of PfEMP1 on the
surfaceofCS2andCS2DPf332wasconﬁrmedbymeasur-
ing the binding of IgG from malaria-exposed individuals to
infected erythrocytes of CS2 and CS2DPf332 (Beeson
et al., 2006). Using serum from malaria-exposed multi-
gravid women from Papua New Guinea, which reacts
predominantly with the PfEMP1 protein encoded by
var2csa,IgGbindingtothesurfaceofinfectederythrocytes
ofCS2andCS2DPf332wasverysimilar(Fig. 7D).Further-
more, rabbit antibodies raised against CS2-infected eryth-
rocytes recognize PfEMP1 (Elliott et al., 2005), labelled
CS2 and CS2DPf332 at similar levels (R1945; Fig. 7A).
Truncation of Pf332 alters P. falciparum-infected
erythrocyte deformability
To assess if Pf332 plays a role in determining erythrocyte
rigidity we used optical magnetic twisting cytometry (Puig-
de-Morales-Marinkovic et al., 2007). This technique
involves small deformations localized mainly to the vicinity
of the bead. Therefore these measurements reﬂect prima-
rily the contribution from the cell membrane, which is
mainly determined by the erythrocyte cytoskeleton (Puig-
de-Morales-Marinkovic et al., 2007). First, we examined
the loss of deformability of the erythrocyte due to the
presence of the parental CS2 at trophozoite stages.
Second, we examined the role of Pf332 in membrane
deformability by comparing CS2Pf332trunc, which has a
greatly truncated C-terminal tail, with CS2DPf322 lacking
the expression of this large protein. The storage modulus
or stiffness, g′, for the CS2-infected erythrocytes (Fig. 8A,
closed data points) shown almost no increase with
increasing frequency. The loss modulus or friction, g″
(Fig. 8A, open data points) was approximately an order of
magnitude smaller than g′, which indicates that the elastic
component clearly dominates. Friction showed a much
stronger dependence upon frequency than did stiffness.
These trends are comparable to those reported previously
Fig. 8. A. Effect of P. falciparum on erythrocyte deformability:
stiffness, g′ (closed data symbols), and friction, g″ (open data
symbols), of CS2 infected erythrocytes, measured at frequencies
from 0.1 to 100 Hz, CS2 (n = 16). Stiffness (grey continuous line)
and friction (grey dashed line) of uninfected erythrocytes. Data
points are geometric means and SD.
B. Stiffness data of CS2Pf332trunc- (n = 18) and CS2DPf332-
(n = 15) infected erythrocytes, normalized by the parental line CS2.
All data are geometric means and SE, and are taken at 0.75 Hz.
Black dashed line at 100% represents CS2 and grey dashed line is
the stiffness of the uninfected erythrocytes.
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pared with uninfected erythrocytes (Fig. 8, grey line), we
found that the presence of the parasite stiffens the cell
membrane by more than twofold. Regardless of the para-
site, frequency dependencies of g′ and g′′ were similar to
those seen with the parental line (data not shown). There-
fore, to quantify the effect of Pf332 truncation or null
expression we ﬁrst focused upon responses of g′ mea-
sured at 0.75 Hz. For the speciﬁc purpose of comparison
between CS2Pf332trunc and CS2DPf332, normalized
means are plotted with standard error (Fig. 8B, data
points). We have also included the median stiffness value
of uninfected cells (47%). While the median stiffness of
the CSPf332trunc-infected erythrocytes is ~85%, repre-
senting ~15% decrease, the more appropriate compari-
son is the change in stiffness relative to that associated
with infection. In particular, this shows that ~30% of the
difference in membrane hardening due to the presence of
the parasite is related to the truncation of Pf332.
We checked for signiﬁcance between the three groups
(CS2, CS2Pf332trunc and CS2DPf332) at that particular
frequency and found that there was little change in g′
for CS2DPf332 compared with CS2 but a signiﬁcant
decrease for CS2Pf332trunc compared with CS2
(P < 0.05). We then extended the comparison to the entire
frequency range (see Experimental procedures) and we
corroborated our ﬁndings. The comparison between CS2-
and CS2Pf332trunc-infected erythrocytes showed statis-
tical signiﬁcance (P < 0.0005) while the comparison
between CS2 and CS2DPf332 did not.
Discussion
Following merozoite invasion P. falciparum initiates a
remarkable remodelling process making the host erythro-
cyte more rigid and able to adhere to receptors (see for
review Marti et al., 2005). This involves export of proteins
that includes Pf332, a large protein that contains a DBL
region, a domain that occurs only within Plasmodia spp.
(Mattei and Scherf, 1992; Gardner et al., 2002). In order
to better understand the role of this domain and the Pf332
protein we expressed a functional form to assess its simi-
larity to the known structures for other DBL domains. The
recombinant DBL domain of Pf332 had physicochemical
properties and a disulphide-bonding pattern consistent
with a correctly refolded protein. In comparison with the
parental disulphide-bond pattern found in the F2 domain
of EBA-175, a disulphide bond from both subregions I and
III were found to have been lost (Tolia et al., 2005). An
additional disulphide bond (Cys-5a–Cys-6a) was also
found in subregion II and formed a surface ridge within the
area equivalent to the hydrophobic pocket of the DARC
binding site in Pk-aDBL (Singh et al., 2006). This disul-
phide bond was validated experimentally and could easily
be accommodated in the modelled structure for the Pf332
DBLdomain. These observations provide strong evidence
that the recombinant Pf332 DBL domain represents a
functional domain.
Although the Pf332 DBL domain has its greatest homol-
ogy to the F2 domain (28% amino acid identity) of EBA-
175, it does not possess the two adjacent DBL domains
found in the R2 region that is a characteristic of the ebl
family. Hence Pf332 structure is not consistent with the
dimerization mechanism of binding proposed for EBA-175
with an F1/F2 domain interaction from two opposing mol-
ecules (Tolia et al., 2005). The construction of the Pf332
molecule is most similar to that found for the more ancient
Duffy-binding proteins found in various Plasmodium spp.
These proteins are type 1 membrane-spanning proteins
which are comprised of: (i) an N-terminal, single DBL
domain which binds DARC on erythrocytes, (ii) a centrally
located cysteine-depleted region, (iii) a small cysteine-rich
domain adjacent to the membrane-spanning region, and
(iv) a small C-terminal cytoplasmic tail. Pf332 does not
have the small cysteine-rich domain adjacent to the
transmembrane-spanning domain and has an extremely
large cytoplasmic tail (> 600 kDa). Comparison between
the modelled structure for Pf332 DBL with that of Pka-
DBL revealed that most of the important features and
residues within this site were not present in the equivalent
region of the Pf332 DBL domain. Hence the structural
features of the Pf332 DBL domain are inconsistent with
involvement in erythrocyte binding via the current docu-
mented mechanisms (Tolia et al., 2005; Singh et al.,
2006). This is consistent with our inability to demonstrate
binding of the Pf332 DBL domain to erythrocytes,
absence of the protein on the red blood cell surface and
lack of release of a soluble form of this domain into the
supernatant after parasite egress.
Previous data have suggested that Pf322 is located on
thesurfaceofthehost-infectederythrocyteandthatitplays
a role in merozoite invasion of erythrocytes perhaps by
initial binding of the DBL domain on the schizont-infected
host cell surface with uninfected erythrocytes (Mattei and
Scherf, 1992; Moll et al., 2007). Earlier studies reported
thatantibodiesraisedtothelargerepetitiveregionofPf332
could inhibit invasion but this was most likely due to the
cross-reactive nature of these antibodies rather than spe-
ciﬁc blocking of protein function (Ahlborg et al., 1995).
More recent data have suggested that antibodies raised to
a GST–Pf332 DBL fusion protein could give at best a very
modest inhibition of merozoite invasion (Moll et al., 2007).
The Pf322 DBL domain expressed in our studies did not
show any binding to red blood cells in contrast to previous
data where this domain was made as a GST chimeric
proteinandalsoexpressedinCHOcells(Mollet al.,2007).
However, the localization of Pf332 is relevant in providing
clues with respect to the possible function of this protein.
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on the surface of P. falciparum-infected erythrocytes. The
protein remains within Maurer’s clefts and is released
during merozoite egress associated with insoluble mem-
branous material. Pf332 is therefore not available to inter-
act with uninfected erythrocytes and is also not associated
with free merozoites so that its subcellular localization is
inconsistent with it playing any role in invasion. This is
consistent with lack of invasion inhibition using antibodies
against the correctly folded DBL domain and also lack of
Pf332 DBLdomain binding to erythrocytes.Also the Pf332
DBL domain shows essentially no sequence diversity in
different parasite strains indicating no selective pressure
bytheimmunesystem.ThisisincontrastwiththeEBA-175
F1/F2 region, an important invasion ligand that shows
considerable diversity as a result of strong selective pres-
sure (Baum et al., 2003). This is consistent with the lack of
exposure of the Pf322 DBL domain on the erythrocyte or
merozoite surface and its lack of involvement in invasion.
As Pf332 remains within Maurer’s clefts in the
P. falciparum-infected erythrocyte it is likely that it serves
a function within the trophozoite and schizont stages. The
most likely possibilities were, ﬁrst, that it is involved in
trafficking the cytoadherence protein PfEMP1 to the host
cell surface and/or, second, that it contributes to the rigidi-
ﬁcation of the parasite-infected erythrocyte. PfEMP1
trafficking was not affected in Pf332 null parasites dem-
onstrating that it was not required for this function at least
in this parasite strain. Nevertheless, we cannot rule out
involvement of this protein in PfEMP1 trafficking, as it is
possible that there is functional redundancy and other
proteins play this role in the absence of Pf332 (Maier
et al., 2008).
The truncation of Pf332 shows a signiﬁcant effect on
the stiffness of the P. falciparum-infected erythrocyte.
Because of the measurement technique, these stiffness
measurements reﬂect mainly the contribution from the
cell membrane and closer vicinities rather than from
other internal sources (Puig-de-Morales-Marinkovic et al.,
2007). Hence, the effect of the truncation on membrane
stiffness, which may be a dominant-negative effect, is
consistent with a role for the large cytoplasmic tail of
Pf332 interacting with the already remodelled membrane
cytoskeleton. The stiffness data and protein location com-
bined suggest that Pf332 may contribute to the rigidity of
the parasite-infected host and in particular Pf332 DBL
domain may be involved in anchoring and scaffolding.
While this work was in review a similar study was pub-
lished showing that loss of Pf332 expression resulted in
increased rigidity of the P. falciparum-infected erythrocyte
consistent with the results observed here (Glenister et al.,
2008). Additionally, they found that PfEMP1 trafficking
was decreased resulting in less of the adherence protein
on the erythrocyte surface. There are two possible
reasons for the differences observed with our work. First,
we have used the strain CS2 that expresses higher levels
of PfEMP1 while they used 3D7 and it is possible the
disparate results could be explained by expression of
different redundant genes involved in the same process.
Second, it is possible that they are observing a dominant
negative effect in which truncated Pf332 is interfering with
trafficking of PfEMP1 and that it does not act directly in
this process. We strongly favour the latter explanation and
this would be similar to a previous study by us in which a
truncated PfEMP3 protein caused decreased PfEMP1
trafficking to the erythrocyte surface by physical blockage
rather than the full-length protein playing any essential
role in the process (Waterkeyn et al., 2000).
Unexpectedly, the complete removal of Pf332 function
had no effect on membrane stiffness. Given the results
with the truncated protein, a plausible explanation is that
there is protein redundancy. In the case of the CS2Df332
parasite the full deletion of Pf332 does not affect erythro-
cyte rigidity suggesting that there are many parasite pro-
teins involved in determining this phenotype, which may
overlap in parasite function. Indeed, we have recently
identiﬁed other proteins that may play a role in determin-
ing the overall rigidity of the P. falciparum-infected eryth-
rocyte (Maier et al., 2008). However, in the case of the
CS2Pf332trunc parasite Pf332 is still present although
truncated, and consequently occupying the place of other
proteins. This idea is also supported by the fact that there
is a small reduction in PfEMP1 trafficking in the parasites
expressing the truncated protein but not the knockout
parasites. Taken together these results indicate that other
proteins are also involved in the loss of deformability and
that the parasite may use redundancy as a strategy.
The experiments presented here have deﬁned the dis-
ulphide bonds of the Pf332 DBL domain suggesting that
there is similarity with those of Pka-DBL and EBA-175
(Tolia et al., 2005; Singh et al., 2006). While the DBL
domain is Plasmodium spp. speciﬁc it is present in a large
number of proteins with differing functions. The DBL
domain is important in binding to proteins and it is pos-
sible that in Pf332 this domain interacts with proteins in
Maurer’s cleft.
Experimental procedures
Cloning, expression and puriﬁcation
The Pf332 DBL domain including residues S10 to A262 was
inserted into the expression vector pProExHTb (Invitrogen,
Carlsbad, CA, USA) with an N-terminal hexa-His tag. It was
produced and puriﬁed in a manner similar to that described
previously (Hodder et al., 2003). Brieﬂy, the protein was syn-
thesized in E. coli strain BL21(DE3) for 3 h at 37°C and
deposited in insoluble inclusion bodies. The cells were lysed
by sonication and the insoluble inclusion bodies solubilized
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protein was isolated by metal-chelate chromatography using
Ni-NTA agarose resin (Qiagen, Hilden, Germany), and eluted
in 8 M urea, 1 M imidazole, pH 8.0. The protein was diluted
100-fold and refolded at room temperature for 24 h in 2 M
urea, 100 mM NaCl, 20 mM Tris pH 8.0, with 1 mM reduced
and 1 mM oxidized glutathione included to facilitate disul-
phide bond formation. One tablet of Complete Protease
inhibitors (Roche, Basel, Switzerland) was added per 200 ml
of refold solution to prevent unwanted degradation of Pf332
in the refold mixture. Refolded protein was isolated by
anion-exchange chromatography and fractions containing
monomer were pooled for further use.
RP-HPLC analysis of the refolding reaction
RP-HPLC was performed using an Agilant 1100 modular
HPLC consisting of an on-line degasser, piston pump,
autosampler, column oven, diode-array detector and fraction
collector. Instrument control, data acquisition and evaluation
were performed using Hewlett–Packard Chemstation soft-
ware for LC and LC/MS systems. Buffer A was comprised
0.05% (v/v) triﬂuoroacetic acid (HPLC/Spectro grade, Pierce,
Rockford, IL, USA) in Milli-Q grade water (Millipore, Bedford,
MA, USA), while buffer B was comprised of 0.05% (v/v)
triﬂuoroacetic acid in acetonitrile (ChromAR HPLC grade,
Malinckrodt, Paris, KY, USA). Aliquots from the refold mixture
were centrifuged at 14000 r.p.m. for 15 min at room tempera-
ture prior to loading onto a C8 column [2.1 mm inner
diameter ¥ 100 mm (Brownlee columns, Perkin-Elmer Instru-
ments, Norwalk, CT, USA)] in the presence of bufferA. Bound
proteins were eluted using a linear gradient of 0–100% buffer
B over 12 min at a ﬂow rate of 0.5 ml min
-1 at 37°C.
Production of antibodies
Polyclonal and monoclonal antibodies against the refolded
recombinant antigen were generated in rabbits and mice, with
each animal receiving a minimum of three immunizations prior
to assessing the reactivity of the antibodies to the parasite
antigen on immunoblots and immunoﬂuorescence assays.
SDS-PAGE and immunoblots procedures
Parasite cultures were synchronized by treatments with sor-
bitol (Lambros and Vanderberg, 1979), and in some cases
enriched by percoll puriﬁcation (Aley et al., 1986). Parasite-
derived proteins were fractionated on Tris-Acetate 3–8%
precast gels (Invitrogen, Carlsbad, CA, USA) using the
manufacturer’s running buffer. For analysis of the high-
molecular-weight forms of Pf332 found in parasites, electro-
phoresis was continued until the 50 kDa marker reached the
bottom of the gels. Recombinant proteins were fractionated
on 4–12% Bis-Tris precast gels (Invitrogen, Carlsbad, CA,
USA) using MES running buffer. Proteins were electropheri-
cally transferred to PVDF membrane (0.22 mm, Millipore, Bil-
lerica, MA, USA). Immunoblotting was performed using
procedures described previously (Hodder et al., 2001). The
following antibodies were used: mouse anti-Pf332 serum
(1:500), mouse anti-Pf332 mAb 10H2 (10 mgm l
-1), mouse
anti-ATS (1B98 6HI) (1:100) (pre-absorbed on erythrocyte
ghosts) and mouse anti-HSP70 (1:2500). Horseradish
peroxidase-coupled sheep anti-mouse Ig (1:2000, Chemicon,
Melbourne,Australia) was used as a secondary antibody. The
protein bands on the immunoblots were visualized using
a chemiluminescent substrate (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions.
Tryptic digestion of refolded Pf332 DBL domain
RP-HPLC puriﬁed Pf332 DBL domain (approximately 6 nmol)
was reduced to half volume using a Centrivap concentrator
(Labconco, Fort Scott, KS, USA). The solution was then
buffered to pH 6.5 using a 1:10 dilution of 1 M sodium phos-
phate,pH 6.5.Proteomicsgradetrypsin(Sigma,StLouis,MO,
USA) in 1 mM HCl was added at an enzyme:protein ratio of
1:25 (w/w), and the solution was incubated at 37°C for 4 h. A
second aliquot of trypsin (1:25 w/w) was then added, and the
mixture incubated for a further 16 h at 37°C. Digestion was
stopped either by snap freezing to -70°C or RP-HPLC.
RP-HPLC determination and fractionation of
disulphide-bonded tryptic peptides from Pf332
DBL domain
Analytical RP-HPLC of either DTT-reduced or non-reduced
Pf332 tryptic digests was used to identify the location of
disulphide-linked peptides within the elution proﬁle in a
manner similar to that described previously (Hodder et al.,
1996). RP-HPLC was conducted using the Agilant 1100
system and buffers described above. An aliquot containing
20 mg of tryptic digest was mixed with an equal volume of 6 M
guanidiniumchloride,0.2 MTris-HCl,pH 8.4,5 mMEDTAand
then reduced by the addition of DTT (ﬁnal concentration,
25 mM) for 60 min at 45°C.Atryptic ﬁngerprint for the reduced
digest was then obtained by eluting the peptide fragments
from a C18 column (4.6 mm inner diameter ¥ 250 mm, Vydac,
Grace Davison, Hesperia, CA, USA) using a 0–70% buffer B
linear gradient over 120 min at 45°C and a ﬂow rate of
1m lm i n
-1. The proﬁle obtained was then compared with the
trypticﬁngerprintobtainedforasimilaramountofnon-reduced
digest eluted under identical chromatographic conditions.The
disappearance of a peak following reduction indicated the
presence of a disulphide-linked peptide. The remainder of the
digest mixture (125 mg) was then fractionated under identical
conditions.The disulphide-containing peptides were collected
and subjected to Edman degradation and ion-trap mass-
spectrometric analysis.
Edman degradation and mass spectrometric analyses of
tryptic peptides
RP-HPLC fractions were subjected to direct amino acid
sequence analysis (Edman degradation) with pulsed-liquid
delivery of critical reagents in an automated sequenator
(Model 492, Applied Biosystems, Foster City, CA, USA). Indi-
vidual fractions were infused directly into the nanospray ion
source of the a LCQ Classic quadrupole ion-trap mass spec-
trometer (Thermo) with the following settings: nanospray tip
voltage 2.3 kV, capillary temperature 150°C, capillary voltage
24 V, tube lens offset 5 V. The AspN subdigestion of tryptic
fragment #35 (approximately 1 mg as determined by Edman
degradation results) was done as per manufacturer’s recom-
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sequencing grade enzyme in 50 mM sodium phosphate,
pH 8.0 solution at an enzyme:peptide ration of 1:20 for 2 h at
37°C. The subdigest of tryptic fraction #35 was analysed after
clean-up on C18 ZipTip (Millipore, Bedford, MA, USA)
by RP-HPLC on a C18 column (3 mm, 0.15 mm inner
diameter ¥ 150 mm, Vydac) using a Surveyor-MS HPLC
system (Thermo, San Jose, CA, USA). Mobile-phase buffers
were 0.2% (v/v) formic acid in water (buffer A) and 0.2% (v/v)
formic acid in acetonitrile (buffer B), and were run at a ﬂow
rate of 1 ml min
-1 with a linear gradient of 5–95% buffer B over
20 min, held at 95% buffer B for 10 min and ﬁnally 95–5%
buffer B over 2 min. The effluent from the column was con-
nected directly to the nanospray ion source of the LCQ
MS. MS-Bridge software (http://prospector.ucsf.edu/cgi-bin/
msform.cgi?form=msbridgestandard) was used to identify
molecular ions corresponding to the expected theoretical
cleavage products of tryptic fraction #35.
Modelling of the Pf332 DBL domain
The model of Pf332 was created with the MODELLER (6v2)
program (Fiser and Sali, 2003) using the X-ray crystal struc-
ture of EBA-175 (domain 2) (Tolia et al., 2005) (PDB access
code 1ZRO) as a template, and the sequence alignment
shown in Fig. S1. From 25 initial models the structure with
lowest Modeller Objective Function was subjected to molecu-
lar dynamics (MD) simulation. All MD calculations were per-
formed using the GROMACS (v3.1.4) package of programs
(Lindahl, 2001) with the OPLS-aa force ﬁeld (Smith et al.,
1998). The protein was placed in a 90 ¥ 90 ¥ 90 Å
3 water box
with no pressure coupling. Ionizable residues were assumed
to be in their standard state at neutral pH – the total charge on
the system was made neutral by replacing water molecules
with sodium ions. The LINCS algorithm (Hess et al., 1997)
was used to constrain bond lengths. Peptide, water and ions
were coupled separately to a thermal bath at 300 K using a
Berendsen thermostat (Berendsen et al., 1984) applied with
a coupling time of 0.1 ps. All simulations were applied with a
single non-bonded cut-off of 10 Å, using a neighbour-list
update frequency of 10 steps (20 fs). The particle-mesh
Ewald method was applied to deal with long-range electro-
statics – a grid width of 1.2 Å was used with a forth-order
spline interpolation.All simulations consisted of an initial mini-
mization of water molecules followed by 10 ps of MD with
the protein ﬁxed. Following positional restraints MD, the
restraints on the protein were removed and MD continued for
a further 1 ns. The time-step used in all MD simulations was
2 fs. At the completion of the MD calculation the system was
minimized using the method of steepest descents.
Plasmid construction, parasite strains, culture conditions
and transfection
A deletion construct was generated by insertion of a 5′ [619
base pairs (bp)] and 3′ (512 bp) segment of Pf332 into pCC-1
(Maier et al., 2008), with SacII/SpeI and EcoRI/NcoI. The
segments were ampliﬁed from CS2 genomic DNAusing oligo-
nucleotide primers aw814/aw815 and aw816/aw817 respec-
tively. The truncation plasmid was derived from pHHT-TK
(Maier et al., 2006) by insertion of a 5′ ﬂank (901 bp, ampliﬁed
by aw152/153) and a 3′ ﬂank (939 bp, ampliﬁed by aw154/
155) using SacII/SpeI and EcoRI/AvrII as restriction enzymes.
Plasmodium falciparum asexual stages of the CS2 clone
(Duffy et al., 2006) were maintained in human 0+ erythrocyte.
Transfection with 100 mg of puriﬁed plasmid DNA (Qiagen,
Hilden, Germany and Invitrogen, Carlsbad, CA, USA) and
selection for stable transfectants were carried out as
described (Maier et al., 2006; 2008).
Oligonucleotides and DNA analysis
The following oligonucleotides were used:
Aw152: atcccgcggaagaggatgtgcaggaattag,
Aw153: gatactagtctactggtaactcttctatgggac,
Aw154: atcgaattcggatcagtcactgaacaacttgttg,
Aw155: gatcctaggcacctttagtgtgtatatcagcagtag,
Aw814: atcccgcggtgtagaacttatgctg,
Aw815: gatactagtctctcatcatgcttctcacg,
Aw816: ggtgagagtattatggatagaattcc,
Aw817: ggatccatggtttctaattcctgcacatcctc.
Restriction sites introduced for cloning purposes are under-
lined. Genomic DNAwas prepared with the DNeasyTissue Kit
(Qiagen) and subjected to Southern Blot analysis using the
Roche DIG system following the manufacturer’s instructions.
Trypsin cleavage assay
Parasites were synchronized by sorbitol and enriched by
gelofusin ﬂoatation (Braun, Melsungen, Germany) at
the early trophozoite stage. The cells were then treated
with either TPCK-treated trypsin (Sigma) 1 mg ml
-1 in PBS
or TPCK-treated trypsin plus soybean trypsin inhibitor
(5 mg ml
-1 in PBS, Worthington, Lakewood, NJ, USA) or PBS
alone for 1 h at 37°C. After incubation soybean trypsin inhibi-
tor was added followed by incubation at room temperature for
15 min. Cell pellets were lysed with Triton X-100 (1%), and
insoluble proteins were collected and re-suspended in SDS
(2%) as described (Waterkeyn et al., 2000) before use in
Western blotting.
Immunoﬂuorescence and transmission electron
microscopy
For immunoﬂuoresence analysis, either acetone/methanol
(90%/10%) ﬁxed smears or live cells of asynchronous para-
sites of CS2DPf332-, CS2truncPf332- and CS2-infected
erythrocytes were used.After washing in PBS and blocking in
0.5% BSA the samples were probed with either polyclonal
rabbit or monoclonal mouse anti-Pf332 (1:500), rabbit anti-
SBP1 (1:500), rabbit anti-MSP1 (1:200), rabbit anti-ATS
(1:200), rabbit anti-PfEMP3 (1: 2000) or with human serum
from a malaria-endemic area in Kenya (1:20) and conse-
quently incubated with secondary antibodies Alexa-Fluor
488-conjugated anti-rabbit IgG (Molecular Probes) and
Alexa-Fluor 594-conjugated anti-mouse IgG (Molecular
Probes). Cells were viewed with an Apochromat 100¥/1.4 oil
lense on a Zeiss Axioskop 2 microscope equipped with a
PCO SensiCam (12bit) camera and Axiovision 3 software.
Captured images were processed using Photoshop and
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tures were adjusted to gain optimal contrast to visualize fea-
tures of interest. For transmission electron microscopy wild-
type CS2-infected erythrocytes were magnet-puriﬁed at the
trophozoite stage and high pressure frozen, freeze substi-
tuted and processed further as described earlier (Rug et al.,
2004). Ultra-thin sections were probed with polyclonal rabbit
or monoclonal mouse anti-Pf332 (1:100), followed by gold-
conjugated anti-rabbit (20 nm) or anti-mouse (10 nm) IgG,
stained additionally for contrast as described earlier
(Rug et al., 2004) and subsequently viewed under a Philips
CM transmission EM at 120 kV.
Flow cytometry
Binding of antibodies (human, rabbit and monoclonal) to the
surface of P. falciparum-infected erythrocytes was measured
by ﬂow cytometry using established methods (Beeson et al.,
2004). P. falciparum mature trophozoite stage-infected eryth-
rocytes were tested at 2–4% parasitaemia and 0.2%
haematocrit. Where infected erythrocytes were tested for
binding of antibodies in human sera, cells were sequentially
incubated with test serum (1/20), rabbit anti-human
IgG (Dako) and Alexa-Fluor 488-conjugated anti-rabbit
IgG (Molecular Probes, 1:1000), with ethidium bromide
(10 mgm l
-1) in darkness. When using rabbit antibodies
(R1945), cells were sequentially incubated with rabbit antise-
rum (1/25) and Alexa-Fluor 488-conjugated anti-rabbit IgG.
When using monoclonal antibodies, cells were sequentially
incubated with monoclonal antibody and Alexa-Fluor 488-
conjugated anti-mouse IgG. All incubations were performed
in PBS with 0.1% casein for 30 min at room temperature. For
each sample, IgG binding was expressed as the geometric
mean ﬂuorescence intensity (MFI) for infected erythrocytes
(ethidium bromide positive), after subtracting MFI for unin-
fected erythrocytes. Sera from non-exposed donors and posi-
tive control samples were included in each assay.
Rabbit antiserum R1945 was generated by immunization
of rabbits with CS2-infected erythrocytes; it has been previ-
ously shown to recognize var2csa-PfEMP1 (Elliott et al.,
2005). Human serum samples used in assays were collected
from malaria-exposed pregnant women who were residents
of the Madang Province, Papua New Guinea (PNG), present-
ing for routine antenatal care at the Modilon Hospital,
Madang from 2001 to 2002 (Beeson et al., 2007). Serum
from ﬁve Australian residents were included as controls.
Informed consent was given by all donors and ethical clear-
ance was obtained from the Medical Research Advisory
Committee, Department of Health, PNG, and the Human
Research Ethics Committee of the Walter and Eliza Hall
Institute.
Ferrimagnetic microbeads and binding
Ferrimagnetic beads (solid Fe3O4, 2.3 mm) were prepared as
previously described (Puig-de-Morales-Marinkovic et al.,
2007). Brieﬂy, beads were coated with Concanavalin A
(ConA, Sigma, St Louis, MO, USA) by incubating overnight at
4°C in ConA solution (1 mg ml
-1). ConA is not blood group
speciﬁc but has an affinity for terminal a-D-mannosyl and
a-D-glucosyl residues. A wide variety of serum and trans-
membrane glycoproteins have a ‘core oligosaccharide’ struc-
ture, which includes a-linked mannose residues.
Magnetic twisting cytometry with optical detection
The experimental set-up is described elsewhere (Fabry et al.,
2001; 2003). Brieﬂy, cells adherent to the bottom of a glass
well with beads attached to their surface were placed on an
inverted microscope (Leica DM IRBE, Leica Microsystems,
Weitzler, Germany) and viewed under bright ﬁeld with an oil
immersion 63¥ objective and optically magniﬁed 1.5¥. Beads
were ﬁrst magnetized horizontally, then subjected to a oscil-
latory magnetic ﬁeld in the vertical direction. This oscillatory
ﬁeld causes a speciﬁc torque on the bead. The lateral dis-
placements of the bead in response to the oscillatory torque
were tracked using a CCD camera (JAI CV-M10, Gloatrup,
Denmark) with an exposure time of 0.1 ms and acquisition
frequency of 24 Hz. The bead position was computed using
an intensity-weighted centre-of-mass algorithm (Fabry et al.,
2001).
Mechanical tests
Clean, 35 mm glass-bottom wells (MatTek, Ashland, MA,
USA) were covered with 0.1 mg ml
-1 poly-L-lysine (Sigma, St
Louis, MO, USA) for 5 min at room temperature. P. falciparum
erythrocytes were allowed to adhere for 10 min to the wells
before the beads were added. Measurements were per-
formed at oscillatory frequencies between 10
-1 and 10
2 Hz.
As described previously, heterodyning was used when the
sinusoidal forcing frequency was greater than 4 Hz (Fabry
et al., 2001). All measurements using infected cells were
performed at trophozoite stage, as they were clearly recog-
nized under the microscope.
Measurement of the complex viscoelastic modulus and
statistical analysis
Storage modulus or stiffness, g′, and loss modulus or friction,
g″, were extracted from the torque and corresponding lateral
bead displacement as described elsewhere (Fabry et al.,
2003; Puig-de-Morales-Marinkovic et al., 2007).
We checked for signiﬁcance between the three groups
(CS2, CS2Pf332trunc and CS2DPf332) using two different
approaches. The ﬁrst approach was focusing upon the stiff-
ness responses at one particular frequency (0.75 Hz). We
applied a Student’s t-test between CS2 and CS2Pf332trunc,
and between CS2 and CS2DPf332. The second approach
was extending the comparison between stiffness responses
across frequencies. We ﬁt the mean data for each group to
the model G*(s) = A + Bs
a, where G*(s) is the complex elastic
modulus in Laplace space (see for details Puig-de-Morales-
Marinkovic et al., 2007). This model reﬂects the behaviour
seen in Fig. 8A. Within each group we also estimated the
standard error of the parameter A, because it is the dominant
term describing the data in Fig. 8A and in particular describ-
ing the stiffness data. We compared both CS2Pf332trunc and
CS2DPf332 with the parental line CS2 by examination of the
z-statistics for differences in the parameter A. All data pre-
sented are geometric means and SD or SE.
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